Mostrar el registro sencillo del ítem

dc.contributor.authorDetalle, Laurent
dc.contributor.authorStohr, Thomas
dc.contributor.authorPalomo-Sanz, Concepcion 
dc.contributor.authorPiedra, Pedro A
dc.contributor.authorGilbert, Brian E
dc.contributor.authorMas-Lloret, Vicente 
dc.contributor.authorMillar, Andrena
dc.contributor.authorPower, Ultan F
dc.contributor.authorStortelers, Catelijne
dc.contributor.authorAllosery, Koen
dc.contributor.authorMelero, Jose Antonio 
dc.contributor.authorDepla, Erik
dc.date.accessioned2020-05-08T06:44:01Z
dc.date.available2020-05-08T06:44:01Z
dc.date.issued2016
dc.identifier.citationAntimicrob Agents Chemother. 2015 Oct 5;60(1):6-13.es_ES
dc.identifier.issn0066-4804es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9964
dc.description.abstractRespiratory syncytial virus (RSV) is an important causative agent of lower respiratory tract infections in infants and elderly individuals. Its fusion (F) protein is critical for virus infection. It is targeted by several investigational antivirals and by palivizumab, a humanized monoclonal antibody used prophylactically in infants considered at high risk of severe RSV disease. ALX-0171 is a trimeric Nanobody that binds the antigenic site II of RSV F protein with subnanomolar affinity. ALX-0171 demonstrated in vitro neutralization superior to that of palivizumab against prototypic RSV subtype A and B strains. Moreover, ALX-0171 completely blocked replication to below the limit of detection for 87% of the viruses tested, whereas palivizumab did so for 18% of the viruses tested at a fixed concentration. Importantly, ALX-0171 was highly effective in reducing both nasal and lung RSV titers when delivered prophylactically or therapeutically directly to the lungs of cotton rats. ALX-0171 represents a potent novel antiviral compound with significant potential to treat RSV-mediated disease.es_ES
dc.description.sponsorshipThis work was supported by the Agentschap voor Innovatie door Wetenschap en Techniek (IWT), Belgium (grant numbers 100333 and 130562). Work in Madrid was partially supported by grant SAF2012-31217 to J.A.M. from Plan Nacional I+D+i.es_ES
dc.language.isoenges_ES
dc.publisherAmerican Society for Microbiology (ASM) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshAdministration, Inhalation es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshAntibodies, Neutralizing es_ES
dc.subject.meshAntibodies, Viral es_ES
dc.subject.meshAntiviral Agents es_ES
dc.subject.meshFemale es_ES
dc.subject.meshGene Expression es_ES
dc.subject.meshHumans es_ES
dc.subject.meshLung es_ES
dc.subject.meshMale es_ES
dc.subject.meshModels, Moleculares_ES
dc.subject.meshNasal Cavity es_ES
dc.subject.meshNeutralization Tests es_ES
dc.subject.meshPalivizumab es_ES
dc.subject.meshPichia es_ES
dc.subject.meshRats es_ES
dc.subject.meshRecombinant Proteins es_ES
dc.subject.meshRespiratory Syncytial Virus Infections es_ES
dc.subject.meshRespiratory Syncytial Viruses es_ES
dc.subject.meshSigmodontinae es_ES
dc.subject.meshSingle-Domain Antibodies es_ES
dc.subject.meshViral Fusion Proteins es_ES
dc.subject.meshViral Load es_ES
dc.subject.meshViruses_ES
dc.titleGeneration and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infectiones_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID26438495es_ES
dc.format.volume60es_ES
dc.format.number1es_ES
dc.format.page6-13es_ES
dc.identifier.doi10.1128/AAC.01802-15es_ES
dc.contributor.funderAgency for Innovation by Science and Technology (Belgica) 
dc.identifier.e-issn1098-6596es_ES
dc.identifier.journalAntimicrobial agents and chemotherapyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/100333es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/130562es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/SAF2012-31217es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional